|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0027651,
umls-concept:C0030705,
umls-concept:C0033684,
umls-concept:C0042196,
umls-concept:C0205195,
umls-concept:C0205390,
umls-concept:C0205470,
umls-concept:C0677907,
umls-concept:C0936012,
umls-concept:C1510427,
umls-concept:C1522673,
umls-concept:C2603343
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-2-10
|
|
pubmed:abstractText |
In a phase I/II study, patients with solid metastatic MAGE-3-positive tumors, mainly melanoma, were vaccinated with recombinant MAGE-3 protein combined with the immunologic adjuvant AS02B comprised of MPL and QS21 in an oil-in-water emulsion. The recombinant MAGE-3 protein was made up of a partial sequence of the protein D (ProtD) antigen of Haemophilus influenzae fused to the MAGE-3 sequence. The vaccine was given intramuscularly at 3-week intervals. Patients whose tumors stabilized or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. MAGE-3 and ProtD antibody and cellular immune responses were monitored after vaccination. Ninety-six percent (23/24) of the patients vaccinated with MAGE-3 protein in AS02B adjuvant elicited a significant anti-MAGE-3 IgG antibody response after 4 vaccinations, and all developed anti-ProtD IgG antibodies. For the detection of T-cell activity, total peripheral blood mononuclear cells were restimulated in vitro with MAGE-3- or ProtD-loaded autologous mature dendritic cells. In 30% of the evaluable patients vaccinated with the adjuvanted recombinant protein, IFNgamma production was increased in response to MAGE-3, and 2 patients (14% of evaluable patients) had a concomitant increase in IL-5 production. In 37% and 43% of the patients, respectively, IFNgamma or IL-5 production was increased in response to ProtD. It is concluded that vaccination of advanced cancer patients with MAGE-3 self-antigen in AS02B adjuvant is able to elicit MAGE-3-specific antibody and a T-cell response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Bacterial Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Carrier Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin D,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-5,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/MAGEA3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/glpQ protein, Haemophilus influenzae
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1524-9557
|
|
pubmed:author |
pubmed-author:AmraniNoreddineN,
pubmed-author:BrittenCedrik MCM,
pubmed-author:BruckClaudineC,
pubmed-author:DantinneChristineC,
pubmed-author:DelireMarcelM,
pubmed-author:GheysenDirkD,
pubmed-author:GuéguenMaryseM,
pubmed-author:KeilholzUlrichU,
pubmed-author:LamersCor H JCH,
pubmed-author:MarchandMarieM,
pubmed-author:PermannePhilippeP,
pubmed-author:StoterGerritG,
pubmed-author:VantommeValérieV
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
124-35
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:14770084-Animals,
pubmed-meshheading:14770084-Antigens, Neoplasm,
pubmed-meshheading:14770084-Bacterial Proteins,
pubmed-meshheading:14770084-Blotting, Western,
pubmed-meshheading:14770084-CHO Cells,
pubmed-meshheading:14770084-Cancer Vaccines,
pubmed-meshheading:14770084-Carrier Proteins,
pubmed-meshheading:14770084-Cricetinae,
pubmed-meshheading:14770084-Cytokines,
pubmed-meshheading:14770084-Dendritic Cells,
pubmed-meshheading:14770084-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:14770084-Escherichia coli,
pubmed-meshheading:14770084-Haemophilus influenzae,
pubmed-meshheading:14770084-Humans,
pubmed-meshheading:14770084-Immunoglobulin D,
pubmed-meshheading:14770084-Immunotherapy,
pubmed-meshheading:14770084-Insects,
pubmed-meshheading:14770084-Interferon-gamma,
pubmed-meshheading:14770084-Interleukin-5,
pubmed-meshheading:14770084-Leukocytes, Mononuclear,
pubmed-meshheading:14770084-Lipoproteins,
pubmed-meshheading:14770084-Neoplasm Proteins,
pubmed-meshheading:14770084-Neoplasms,
pubmed-meshheading:14770084-Recombinant Fusion Proteins,
pubmed-meshheading:14770084-T-Lymphocytes,
pubmed-meshheading:14770084-Time Factors,
pubmed-meshheading:14770084-Treatment Outcome
|
|
pubmed:articleTitle |
Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.
|
|
pubmed:affiliation |
GlaxoSmithKline Biologicals, Rixensart, Belgium.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
